FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159355795> ?p ?o ?g. }

• W2159355795 endingPage "840" @default.
• W2159355795 startingPage "835" @default.
• W2159355795 abstract "Both gemcitabine and etoposide are active in the treatment of small-cell lung cancer (SCLC), and are characterised by mild toxicity profiles. The combination of both drugs was found to be feasible and active in a phase I dose-finding study in solid tumours. Therefore, a phase II trial was initiated to examine the activity and toxicity of this schedule in extensive disease SCLC.Forty-two chemo-naïve extensive disease SCLC patients were enrolled to receive gemcitabine 1000 mg/m2, days 1, 8 and 15, and etoposide 80 mg/m2, days 8, 9 and 10 of a 28-day cycle.Thirty-seven patients were evaluable for efficacy (five received less than one cycle). No complete responses were observed, but partial responses were seen in 17 patients, yielding an overall response rate of 46%. The median duration of response was 5.8 months. Disease stabilisation was obtained in another 10 patients (27%). The median survival of the 37 protocol-qualified patients was 10.5 months (95% confidence interval (CI): 7.5-12.0). The levels of WHO grade 3 and 4 toxicities were low and clinically manageable.In comparison with standard platinum-based regimens, this combination of gemcitabine and etoposide resulted in a somewhat lower response rate, but a similar median survival time. Haematological toxicity was more pronounced than expected from the toxicity data of each agent individually. However, because of its mild non-haematological toxicity, and its ability to be administered in an outpatient setting, this combination provides a reasonable palliative option for patients with extensive disease SCLC." @default.
• W2159355795 created "2016-06-24" @default.
• W2159355795 creator A5004056411 @default.
• W2159355795 creator A5007889470 @default.
• W2159355795 creator A5012625053 @default.
• W2159355795 creator A5019435731 @default.
• W2159355795 creator A5021072105 @default.
• W2159355795 creator A5021704329 @default.
• W2159355795 creator A5026119562 @default.
• W2159355795 creator A5029862849 @default.
• W2159355795 creator A5062933842 @default.
• W2159355795 date "2001-06-01" @default.
• W2159355795 modified "2023-10-02" @default.
• W2159355795 title "Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: A multi-centre phase II study" @default.
• W2159355795 cites W1839348318 @default.
• W2159355795 cites W1857358013 @default.
• W2159355795 cites W1858072261 @default.
• W2159355795 cites W1883554783 @default.
• W2159355795 cites W1907795058 @default.
• W2159355795 cites W1961129053 @default.
• W2159355795 cites W1963786241 @default.
• W2159355795 cites W1998669907 @default.
• W2159355795 cites W2001996041 @default.
• W2159355795 cites W2032514086 @default.
• W2159355795 cites W2041808533 @default.
• W2159355795 cites W2055045896 @default.
• W2159355795 cites W2083817990 @default.
• W2159355795 cites W2097597328 @default.
• W2159355795 cites W2122995772 @default.
• W2159355795 cites W2123586708 @default.
• W2159355795 cites W2123767004 @default.
• W2159355795 cites W2130164889 @default.
• W2159355795 cites W2154060376 @default.
• W2159355795 cites W2159875696 @default.
• W2159355795 cites W2162629228 @default.
• W2159355795 cites W2167805334 @default.
• W2159355795 cites W2172820356 @default.
• W2159355795 cites W2323020638 @default.
• W2159355795 cites W2417042318 @default.
• W2159355795 cites W2992760141 @default.
• W2159355795 doi "https://doi.org/10.1023/a:1011176116567" @default.
• W2159355795 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11484961" @default.
• W2159355795 hasPublicationYear "2001" @default.
• W2159355795 type Work @default.
• W2159355795 sameAs 2159355795 @default.
• W2159355795 citedByCount "15" @default.
• W2159355795 countsByYear W21593557952012 @default.
• W2159355795 countsByYear W21593557952013 @default.
• W2159355795 crossrefType "journal-article" @default.
• W2159355795 hasAuthorship W2159355795A5004056411 @default.
• W2159355795 hasAuthorship W2159355795A5007889470 @default.
• W2159355795 hasAuthorship W2159355795A5012625053 @default.
• W2159355795 hasAuthorship W2159355795A5019435731 @default.
• W2159355795 hasAuthorship W2159355795A5021072105 @default.
• W2159355795 hasAuthorship W2159355795A5021704329 @default.
• W2159355795 hasAuthorship W2159355795A5026119562 @default.
• W2159355795 hasAuthorship W2159355795A5029862849 @default.
• W2159355795 hasAuthorship W2159355795A5062933842 @default.
• W2159355795 hasBestOaLocation W21593557951 @default.
• W2159355795 hasConcept C126322002 @default.
• W2159355795 hasConcept C141071460 @default.
• W2159355795 hasConcept C143998085 @default.
• W2159355795 hasConcept C2776256026 @default.
• W2159355795 hasConcept C2776694085 @default.
• W2159355795 hasConcept C2778119113 @default.
• W2159355795 hasConcept C2778822529 @default.
• W2159355795 hasConcept C2780258809 @default.
• W2159355795 hasConcept C2781047374 @default.
• W2159355795 hasConcept C29730261 @default.
• W2159355795 hasConcept C31760486 @default.
• W2159355795 hasConcept C71924100 @default.
• W2159355795 hasConcept C90924648 @default.
• W2159355795 hasConceptScore W2159355795C126322002 @default.
• W2159355795 hasConceptScore W2159355795C141071460 @default.
• W2159355795 hasConceptScore W2159355795C143998085 @default.
• W2159355795 hasConceptScore W2159355795C2776256026 @default.
• W2159355795 hasConceptScore W2159355795C2776694085 @default.
• W2159355795 hasConceptScore W2159355795C2778119113 @default.
• W2159355795 hasConceptScore W2159355795C2778822529 @default.
• W2159355795 hasConceptScore W2159355795C2780258809 @default.
• W2159355795 hasConceptScore W2159355795C2781047374 @default.
• W2159355795 hasConceptScore W2159355795C29730261 @default.
• W2159355795 hasConceptScore W2159355795C31760486 @default.
• W2159355795 hasConceptScore W2159355795C71924100 @default.
• W2159355795 hasConceptScore W2159355795C90924648 @default.
• W2159355795 hasIssue "6" @default.
• W2159355795 hasLocation W21593557951 @default.
• W2159355795 hasLocation W21593557952 @default.
• W2159355795 hasOpenAccess W2159355795 @default.
• W2159355795 hasPrimaryLocation W21593557951 @default.
• W2159355795 hasRelatedWork W2044517330 @default.
• W2159355795 hasRelatedWork W2045413621 @default.
• W2159355795 hasRelatedWork W2100029565 @default.
• W2159355795 hasRelatedWork W2134237771 @default.
• W2159355795 hasRelatedWork W2159355795 @default.
• W2159355795 hasRelatedWork W2331192179 @default.
• W2159355795 hasRelatedWork W2387790385 @default.
• W2159355795 hasRelatedWork W4361947775 @default.

• next